Loading news...
Alumis Inc. (NASDAQ: ALMS - Get Free Report) was the target of a significant growth in short interest in the month of January. As of January 15th, there was short interest totaling 8,672,088 shares, a growth of 93.1% from the December 31st total of 4,492,125 shares. Based on an average daily trading volume, of 10,417,053 shares,
In the past week, a beneficial owner has continued to build a stake in insurance giant W.R.
Acquisition of 588,235 shares at $17.00 per share, representing a total transaction value of ~$10.0 million as of Jan. 9, 2026. This purchase represented 46.49% of Srinivas Akkaraju's previously reported indirect holdings.
The Russell 2000 is beating the S&P 500 for 10 straight sessions as growth accelerates and small-cap earnings expectations rise.
Alumis Inc. (NASDAQ: ALMS - Get Free Report) traded up 6.6% during mid-day trading on Wednesday following insider buying activity. The stock traded as high as $23.94 and last traded at $23.5690. 1,274,140 shares were traded during trading, a decline of 89% from the average session volume of 11,453,423 shares. The stock had previously closed at
Alumis Inc. (NASDAQ: ALMS - Get Free Report) major shareholder Foresite Labs, Llc purchased 411,764 shares of Alumis stock in a transaction dated Thursday, January 8th. The shares were acquired at an average cost of $17.00 per share, with a total value of $6,999,988.00. Following the transaction, the insider directly owned 5,702,536 shares in the company,
Alumis Inc. (NASDAQ: ALMS - Get Free Report) Director Srinivas Akkaraju acquired 588,235 shares of the firm's stock in a transaction that occurred on Friday, January 9th. The shares were purchased at an average price of $17.00 per share, with a total value of $9,999,995.00. Following the completion of the acquisition, the director owned 1,853,488 shares
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the closing of its upsized underwritten public offering of 20,297,500 shares of its common stock, including the full exercise of the underwriters' option to purchase an additional 2,647,500 shares, at a price to the public of $17.00 per share.
SOUTH SAN FRANCISCO, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the pricing of an upsized underwritten public offering of 17,650,000 shares of its common stock at a price to the public of $17.00 per share.
Alumis shares jump 95% after envudeucitinib meets all endpoints in two phase III plaque psoriasis studies, showing strong skin clearance.
Alumis Inc. surged 95% after reporting strong Phase 3 results for lead candidate envudeucitinib in moderate-to-severe plaque psoriasis. Envudeucitinib demonstrated high efficacy for an oral agent, with two-thirds achieving PASI 90 and over 40% reaching complete clearance by Week 24. ALMS announced a $175 million public offering to fund regulatory and clinical advancement, with a 2026 NDA submission targeted.
Alumis (NASDAQ: ALMS) used a conference call to highlight positive top-line Phase III results for envudeucitinib, its next-generation oral TYK2 inhibitor, in adults with moderate to severe plaque psoriasis. Management said the program met all primary and secondary endpoints with "high statistical significance," showed rapid onset of effect, and delivered deepening skin clearance through 24 weeks
Investors today are cheering envudeucitinib's Phase 3 edge in oral TYK2 psoriasis as well as Alumis' plans to raise fresh capital.
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced its plans to commence an underwritten public offering of $175.0 million of shares of its common stock.
Biotech stock Alumis Inc (NASDAQ:ALMS) is skyrocketing today, up 107.9% at $17.28 at last glance, after the Johnson & Johnson (JNJ) rival announced its plaque psoriasis drug, envudeucitinib, met all of its primary and secondary endpoints in both of its phase three trials.
Alumis Inc. (NASDAQ: ALMS) stock is trading higher on Tuesday, with a session volume of 4.33 million compared to the average volume of 1.02 million as per data from Benzinga Pro.
Alumis said on Tuesday its experimental pill met the main goal in two late-stage studies in patients with a type of skin disease.
– Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque psoriasis – – Approximately 65% of patients achieved PASI 90 and more than 40% achieved PASI 100 at Week 24, on average – – Envudeucitinib demonstrated a favorable safety and tolerability profile consistent with the Phase 2 program – – Alumis plans to submit a New Drug Application to the FDA in the second half of 2026 – – Conference call and webcast scheduled for 8:00 a.m. ET today – SOUTH SAN FRANCISCO, Calif.
Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis on Jan 6, 2026
Stock News Prada acquires Versace: Prada Group (HKG:1913) completed a â¬1.25 billion deal to buy Versace from Capri Holdings (CPRI), bringing the brand under t